IL276817A - 7-mutated sulfonimidylfuranone compounds and implications for the treatment and prevention of liver cancer - Google Patents

7-mutated sulfonimidylfuranone compounds and implications for the treatment and prevention of liver cancer

Info

Publication number
IL276817A
IL276817A IL276817A IL27681720A IL276817A IL 276817 A IL276817 A IL 276817A IL 276817 A IL276817 A IL 276817A IL 27681720 A IL27681720 A IL 27681720A IL 276817 A IL276817 A IL 276817A
Authority
IL
Israel
Prior art keywords
prophylaxis
derivatives
treatment
liver cancer
substituted
Prior art date
Application number
IL276817A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL276817A publication Critical patent/IL276817A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL276817A 2018-02-28 2020-08-19 7-mutated sulfonimidylfuranone compounds and implications for the treatment and prevention of liver cancer IL276817A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28
PCT/EP2019/054729 WO2019166432A1 (fr) 2018-02-28 2019-02-26 Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie

Publications (1)

Publication Number Publication Date
IL276817A true IL276817A (en) 2020-10-29

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276817A IL276817A (en) 2018-02-28 2020-08-19 7-mutated sulfonimidylfuranone compounds and implications for the treatment and prevention of liver cancer

Country Status (19)

Country Link
EP (1) EP3758707A1 (fr)
JP (1) JP7089596B2 (fr)
KR (1) KR20200128414A (fr)
CN (1) CN111801100B (fr)
AR (1) AR114419A1 (fr)
AU (1) AU2019228654A1 (fr)
BR (1) BR112020016509A2 (fr)
CA (1) CA3091950A1 (fr)
CL (1) CL2020002139A1 (fr)
CO (1) CO2020010306A2 (fr)
IL (1) IL276817A (fr)
MA (1) MA52412A (fr)
MX (1) MX2020008746A (fr)
PE (1) PE20211456A1 (fr)
PH (1) PH12020551343A1 (fr)
RU (1) RU2020131012A (fr)
SG (1) SG11202008291XA (fr)
TW (1) TW202003518A (fr)
WO (1) WO2019166432A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CN118878544A (zh) 2018-02-28 2024-11-01 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的化合物
KR102409595B1 (ko) 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统
EP4554678A1 (fr) * 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Composés de phosphorylpurinone pour le traitement du cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
AU2010250923A1 (en) * 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
JP5694345B2 (ja) * 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
PL3294740T3 (pl) 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
EP3368092B9 (fr) 2015-10-29 2020-07-29 Novartis AG Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
PL3504210T3 (pl) 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych
EP3512556B1 (fr) * 2016-09-13 2021-08-18 F. Hoffmann-La Roche AG Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b

Also Published As

Publication number Publication date
SG11202008291XA (en) 2020-09-29
CN111801100A (zh) 2020-10-20
PE20211456A1 (es) 2021-08-05
MX2020008746A (es) 2020-09-28
CN111801100B (zh) 2023-10-24
RU2020131012A (ru) 2022-03-28
CA3091950A1 (fr) 2019-09-06
EP3758707A1 (fr) 2021-01-06
KR20200128414A (ko) 2020-11-12
AU2019228654A1 (en) 2020-09-03
PH12020551343A1 (en) 2021-06-21
MA52412A (fr) 2021-06-02
CL2020002139A1 (es) 2021-01-04
TW202003518A (zh) 2020-01-16
JP2021514972A (ja) 2021-06-17
JP7089596B2 (ja) 2022-06-22
WO2019166432A1 (fr) 2019-09-06
CO2020010306A2 (es) 2020-08-31
BR112020016509A2 (pt) 2020-12-15
AR114419A1 (es) 2020-09-02

Similar Documents

Publication Publication Date Title
IL276817A (en) 7-mutated sulfonimidylfuranone compounds and implications for the treatment and prevention of liver cancer
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
ZA201900960B (en) Methods and compositions for the treatment of cancer
GB201820450D0 (en) Compound and its use for the treatment of alpha1-antitryspin deficiency
IL263793A (en) Compounds and preparations for the treatment of cancer
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
IL285807A (en) Immunotherapy for cancer treatment
EP4169918B8 (fr) Dérivés de quinazoline en tant qu'inhibiteurs de pi3k pour le traitement de cancer
SG11202103141YA (en) Combination therapy for the treatment of cancer
LT3924340T (lt) Indazolil-izoksazolo dariniai, skirti ligų, tokių kaip vėžys, gydymui
IL283885A (en) cxcr7 inhibitors for cancer therapy
IL284162A (en) Integrated healing for cancer treatment
EP3630754B8 (fr) Composes d'isoindoline-acetylene pour le traitement du cancer
IL281782A (en) Drug combination for cancer treatment
SG11202000724XA (en) Methods and compositions for the treatment of cancer
ZA202005311B (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
IL280262A (en) Compositions and methods for treating cancer
IL286649A (en) The history of quinoline and its use in cancer treatment
AU2018900827A0 (en) Methods and compounds for the treatment of cancer
EP3876919A4 (fr) Compositions pour le traitement du cancer et d'autres pathologies
AU2018904604A0 (en) Methods and compositions for the treatment of cancer
AU2019900844A0 (en) Methods and compounds for the treatment of cancer
HK40040059A (en) Gremlin-1 antagonist for the prevention and treatment of cancer
HK40063212A (en) Phagocytisable particle for use in the treatment or prophylaxis of cancer
HK40029034A (en) Methods and compositions for the treatment of cancer